Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

by

CTech 24/7

More stories in CTech

Generics

6 stories about Generics

Teva Is Pulling an Ace From its Sleeve in its Attempt to Reinvent Itself
11.11.19|Uri Tal-TeneWith one anti-cancer biosimilar launching this week and another expected to hit the market soon, Teva could be creating a new growth engine worth hundreds of millions of dollars a year
Mylan Cuts Price of Generic Copaxone Offering by 60%
11.07.18|Lilach BaumerMylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
Teva to Relocate U.S. Headquarters to New Jersey
08.07.18|Lilach BaumerIn December, the Israeli drugmaker announced a far-reaching cost cutting plan to deal with its multi-billion debt
Goldman Sachs Sees 16% Upside in Teva Stock
26.06.18|Dror ReichFollowing a meeting with Teva’s management, the bank's analysts reiterated their "buy" recommendation with a higher target price
In Protest of New Bonus Plan, Teva Sued by Israeli Employees
15.03.18|Dror ReichAfter announcing the cancellation of its annual bonuses for 2017 due to debt, the Israel-based drugmaker rolled out a performance-based bonus scheme for 2018 in February
Drugmaker Hikma Appoints Former Teva Executive as CEO
20.02.18|Asaf ShalevThe appointment of Sigurdur Olafsson comes as Hikma has been struggling to bolster the performance of its generic drugs unit

About CTech Terms of Use Privacy Policy

Back to Top